3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark
Stocks like Corcept Therapeutics, Abercrombie & Fitch and HCI Group have been selected as the momentum picks for the day…
52,442$
-4,89%
Echtzeit-Aktienkurs Corcept Therapeutics
Bid:
Ask:
Nachrichten zur Corcept Therapeutics Aktie
Corcept Therapeutics profitiert von höherer Prävalenz bei Hypercortisolismus - Truist sieht Kurspotenzial von 65 %!
Das Biotechunternehmen Corcept Therapeutics (CORT) gilt als Spezialist für die Cortisolmodulation, um die Wirkung des überschüssigen Stresshormons Cortisol im Körper…
Ausblick: Corcept Therapeutics legt Quartalsergebnis vor
Corcept Therapeutics wird am 29.07.2024 das Zahlenwerk zum am 30.06.2024 ausgelaufenen Quartal vorlegen.5 Analysten prognostizieren im Schnitt einen Gewinn je…
SGIOY: 3 Biotech Stocks for Investing in the Future
The biotech sector is primed for robust expansion fueled by the growing needs for personalized medicines and favorable government initiatives.…
Corcept Therapeutics exec sells over $330k in stock By Investing.com
Corcept Therapeutics exec sells over $330k in stock…
Corcept Therapeutics executive sells over $280k in company stock By Investing.com
Corcept Therapeutics executive sells over $280k in company stock…
Earnings call: Corcept Therapeutics raises 2024 revenue guidance By Investing.com
Earnings call: Corcept Therapeutics raises 2024 revenue guidance…
Corcept Therapeutics executive sells over $140k in stock By Investing.com
Corcept Therapeutics executive sells over $140k in stock…
Corcept Therapeutics director sells shares worth over $55k By Investing.com
Corcept Therapeutics director sells shares worth over $55k…
Corcept Therapeutics executive sells over $430k in stock By Investing.com
Corcept Therapeutics executive sells over $430k in stock…
Corcept Therapeutics Stock Is Down 27%. It’s an ‘Ideal Buying Opportunity.’
…
Corcept Therapeutics shares sink after losing patent infringement lawsuit against Teva
Corcept Therapeutics shares fell by more than a quarter on Tuesday morning after a court found against it in a patent…
The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics
Pfizer, Allogene Therapeutics and Corcept Therapeutics are included in this Analyst Blog.…
Corcept Therapeutics plunges amid patent trial with Teva (update)
…
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
Corcept (CORT) delivered earnings and revenue surprises of 66.67% and 7.30%, respectively, for the quarter ended June 2023. Do the…
Insiderhandel: Chief Accounting Officer verkauft Aktien von Corcept Therapeutics im Wert von 236.000$
Lyon, Joseph Douglas - Vorstand - Tag der Transaktion: 2023-06-06...…
Form 8-K CORCEPT THERAPEUTICS For: May 19
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Chief Business Officer verkauft Aktien von Corcept Therapeutics im Wert von 336.980$
Robb, Gary Charles - Vorstand - Tag der Transaktion: 2023-05-10...…
Insiderhandel: Chief Business Officer verkauft Aktien von Corcept Therapeutics im Wert von 716.100$
Robb, Gary Charles - Vorstand - Tag der Transaktion: 2023-05-09...…
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…
Corcept Therapeutics Announces Final Results of Tender Offer
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged…
Corcept Therapeutics Initiates CATALYST Clinical Trial
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged…
Corcept Therapeutics Shares Up About 9% on Tender Offer
Corcept Therapeutics Shares Up About 9% on Tender Offer...…
Corcept Therapeutics gains 10% on share buyback program
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Corcept Therapeutics (CORT) Lags Q4 Earnings and Revenue Estimates
Corcept (CORT) delivered earnings and revenue surprises of -39.13% and 0.66%, respectively, for the quarter ended December 2022. Do the…
Corcept Therapeutics GAAP EPS of $0.15 misses by $0.08, revenue of $103M misses by $2.08M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-K CORCEPT THERAPEUTICS For: Dec 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT
New York, New York--(Newsfile Corp. - January 1, 2023) - WHY: Rosen Law Firm, a global investor rights law firm,…